# US 2021/0332382 A1 · Cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332382 A1
- Document ID: US20210332382A1
- Status: Published application
- Kind: A1
- Application number: 16/982,984
- Filed: 2019-03-19
- Published: 2021-10-28
- Earliest claimed: 2018-03-21
- Assignees: Valo Therapeutics Oy
- Applicants: Valo Therapeutics Oy
- Inventors: Tuuli Ranki; Sari Pesonen; Petri Priha; Erkko Ylösmäki; Vincenzo Cerullo; Beatriz Martins
- Web page: https://patentgrep.com/patent/US20210332382A1

## CPC

- C12N 15/86: Viral vectors
- A61K 35/761: Adenovirus
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/001186: {MAGE}
- A61K 39/001188: {NY-ESO}
- A61K 2039/6031: {Proteins}
- C12N 2710/10332: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention concerns a modified oncolytic adenovirus; a pharmaceutical composition comprising same; and a method of treating cancer using same.

## Claims

### Claim 1

A modified adenovirus comprising:
at least one of the following polypeptides attached covalently or non-covalently onto the viral capsid without having been genetically encoded by said adenoviral vector
i) VFGIELMEVDPIGHLYIFAT [SEQ ID NO:1];
ii) YLAMPFATPMEAELARRSLA [SEQ ID NO:2]; or
iii) a polypeptide that is at least 90% identical therewith.

### Claim 2 (depends on 1)

The modified adenovirus according to claim 1 wherein said polypeptide is poly-lysine extended using at least 3, 4, 5, 6, 7, 8, or 9 lysines.

### Claim 3 (depends on 2)

The modified adenovirus according to claim 2 wherein said lysines are attached at the amino end of the polypeptide.

### Claim 4 (depends on 1)

The modified adenovirus according to claim 1 wherein said polypeptide is
KKKKKK(KKK)-VFGIELMEVDPIGHLYIFAT) [SEQ ID NO:7]; and/or
KKKKKK(KKK)-YLAMPFATPMEAELARRSLA [SEQ ID NO:8]; alternatively:
KKKKKK-VFGIELMEVDPIGHLYIFAT [SEQ ID NO:4]; and/or
KKKKKK-YLAMPFATPMEAELARRSLA [SEQ ID NO:5].

### Claim 5 (depends on 1)

The modified adenovirus according to claim 1 wherein said adenovirus is human adenovirus and/or said adenovirus is of serotype 5.

### Claim 6 (depends on 1)

The modified adenovirus according to claim 1 wherein said adenovirus comprises modifications in E1 and/or E3 and/or E4 and/or L3 genes including insertion of tumour specific promoters, at least one gene deletion and the insertion of at least one transgene.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The modified adenovirus according to claim 1 wherein said adenovirus is further modified to include an Ad5/3 chimeric substitution, wherein the serotype 5 adenoviral fiber knob region is replaced with a serotype 3 adenovirus fiber knob region.

### Claim 9 (depends on 1)

The modified adenovirus according to claim 1 wherein said adenovirus is further modified to include a E1A gene deletion wherein the deletion is of at least those nucleotides encoding amino acids 122-129, and/or said adenovirus is further modified to include partial or complete deletion of the 14.7 k gene.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The modified adenovirus according to claim 1 wherein said adenovirus is further modified to include the insertion of at least one transgene that encodes a co-stimulatory molecule.

### Claim 12 (depends on 11)

The modified adenovirus according to claim 11 wherein said virus includes at least two transgenes wherein one of said transgenes encodes a co-stimulatory molecule that activates the innate immune system and the other encodes a co-stimulatory molecule that activates the adaptive immune system.

### Claim 13 (depends on 12)

The modified adenovirus according to claim 12 wherein said virus includes transgenes encoding CD40L and/or OX40L.

### Claim 14 (depends on 13)

The modified adenovirus according to claim 13 wherein said transgenes are human.

### Claim 15 (depends on 13)

The modified adenovirus according to claim 13 wherein said OX40L, is situated in the E3B region, replacing a gene 14.7K deletion, and/or wherein said CD40L molecule is inserted immediately downstream from OX40L using a 2A processing site.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The modified adenovirus according to claim 1 wherein the peptide to virus ratio is in the range from 1 to 5 μg per 3E+9 Virus Particles.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising at least one modified adenovirus according to claim 1 in combination with a suitable carrier.

### Claim 19 (depends on 18)

The pharmaceutical composition according to claim 18 wherein said composition is formulated for intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intradermal, intracavitary or peritoneal injection, or an oral administration.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 1)

A method of treating cancer in a patient comprising administering to a patient an effective amount of at least one adenovirus according to claim 1.

### Claim 23 (depends on 22)

The method of treating cancer according to claim 22 wherein the at least one adenovirus is administered with a cell checkpoint modulator.

### Claim 24 (depends on 23)

The method of treating cancer according to claim 23 wherein the checkpoint modulator is an anti-PD1 molecule, an anti-PD-L1 molecule or an anti-CTLA-4 molecule.

### Claim 25 (depends on 22)

The method according to claim 22 wherein said cancer includes any one or more of the following cancers: nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.
